Search clinical trials for: BAF312

Total 49 results

Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

Hemorrhagic Stroke | Intracerebral Hemorrhage (ICH)

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions

Neurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, Spastic

Netherlands, Germany, Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

Chronic Ocular Pain

United States, Japan, United Kingdom
Novartis Pharmaceuticals

Completed

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

Postoperative Ocular Pain After PRK Surgery

United States
BioAtla, Inc.

Not yet recruiting

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Advanced Adenocarcinoma
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrolling by invitation

Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

Healthy | Obesity

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of BAF312 in Dermatomyositis

Active Dermatomyositis

United States, Czechia, Japan
Novartis Pharmaceuticals

Completed

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Poland, Hungary, Turkey, Spain, Germany, United States, Canada, Switzerland, Russian Federation, Norway, Italy, Finland
Novartis Pharmaceuticals

Terminated

Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Dermatomyositis | Polymyositis

Hungary, United States, Czechia, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Japan, Bulgaria, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, Slo... and more
Novartis Pharmaceuticals

Completed

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Hepatic Impairment

Hungary, Russian Federation
Novartis Pharmaceuticals

Terminated

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Polymyositis

Hungary, Taiwan, United States, Canada, Czechia, Poland
Novartis Pharmaceuticals

Completed

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Renal Impairment

United States, Romania
Novartis Pharmaceuticals

Completed

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

Hungary, Turkey, Spain, Germany, Canada, Switzerland, United States, Norway, Russian Federation, Italy, Finland, Poland
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (EXCHANGE)

Multiple Sclerosis | Relapsing Multiple Sclerosis | Advancing Multiple Sclerosis

United States, Puerto Rico
LYSOGENE

Active, not recruiting

Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA) (AAVance)

Mucopolysaccharidosis Type IIIA

Germany, United States, United Kingdom, France, Netherlands
Novartis Pharmaceuticals

Completed

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) (AMA-VACC)

Secondary Progressive Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Multiple Sclerosis (MS)

United States, Belgium, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Spain, Argentina, France, Israel, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania and more
Bayer

Completed

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Healthy

Germany
Novartis

Completed

To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients

Postoperative Pain

United States
Bayer

Completed

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox (SPEED)

Maxillary Sinusitis

United States, Argentina
Bayer

Completed

BAY12-8039: 5 Days for Sinusitis vs Placebo

Sinusitis

United States
Bayer

Completed

Greatest International Antiinfective Trial With Avelox (GIANT)

Bronchial Diseases | Bronchitis, Chronic

Switzerland, Poland, China, Croatia, Germany, Hungary, Indonesia, Korea, Republic of, Malaysia, Singapore, Philippines, Taiwan, Austria, Colombia, Hong Kong, Mexico, Slovenia, Turkey, Egypt, Morocco, Netherlands, Pakistan, Brazil, El...
Bayer

Completed

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Infections

United States
Bayer

Completed

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Anti-Infective Agents

Japan
Bayer

Completed

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

Lung Diseases | Bronchitis, Chronic

Italy, Spain, United States, Greece, Chile, Germany, France, Mexico, Argentina, Israel, South Africa, Ireland, Brazil, United Kingdom, Andorra
Bayer

Completed

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB) (SYMPROVE III)

Chronic Bronchitis

Germany
Bayer

Completed

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Abscess, Intra-Abdominal | Secondary Peritonitis

China
Bayer

Completed

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

Electrocardiography | QTc Evaluation

Singapore, Australia, Germany, United Kingdom
Bayer

Completed

Treatment of Patients With Acute Sinusitis

Acute Bacterial Sinusitis

China, France, Germany, Indonesia, Malaysia, Saudi Arabia, Singapore, Philippines, Austria, Jordan, Lebanon, Romania, Bahrain, Egypt, United Arab Emirates, Kuwait, Netherlands, Pakistan, Yemen
Bayer

Completed

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Pneumonia

Croatia, France, Hungary, Jordan, Kazakhstan, Lebanon, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Russian Federation, Ukraine
Bayer

Completed

Avelox in Complicated Skin and Skin Structure Infections (ARTOS)

Skin Diseases, Bacterial

Germany, Indonesia, Korea, Republic of, Saudi Arabia, Philippines, Taiwan, Austria, Bulgaria, Slovenia, Egypt, Greece, Pakistan
Bayer

Completed

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis (VICTOR)

Chronic Bronchitis | Disease Exacerbation

China
Bayer

Completed

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Bronchitis, Chronic

Slovakia, Kazakhstan, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Russian Federation, Ukraine, Bosnia and Herzegovina, Albania
Bayer

Completed

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Healthy

United States
Bayer

Completed

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs (MERAK)

Infectious Diseases

Italy
Bayer

Completed

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

Infection

Belgium, France, Argentina, Spain, Germany, Israel, Romania, Bulgaria, Russian Federation, Lithuania, South Africa, Latvia, Greece, Estonia
Bayer

Completed

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

Pneumonia, Aspiration | Lung Abscess

Germany
Bayer

Completed

Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections) (DRAGON)

Infection, Intra-abdominal

China, Hong Kong, Indonesia, Korea, Republic of, Malaysia, Taiwan
Bayer

Completed

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

Pneumonia

United States, Puerto Rico
Bayer

Terminated

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

Bacterial Infections | Sinusitis

Italy
Bayer

Completed

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin. (MAIDEN)

Pelvic Inflammatory Disease

Germany, Italy, France, Hungary, Sweden, Poland, South Africa, Russian Federation, Finland, Denmark, Lithuania, United Kingdom, Greece
Bayer

Completed

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

Chronic Bronchitis

Spain, China, Argentina, Germany, Greece, Portugal, Canada, Netherlands, Australia, Peru, Philippines, Belgium, Switzerland, Chile, Italy, Thailand, Mexico, Lithuania, South Africa, Croatia, France, Colombia, Indonesia, Latvia, Hong Kong, United Kingdom and more
Bayer

Completed

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

Diabetic Foot | Ulcer | Abscess | Wound Infection

Italy, Spain, Greece, Ireland, Russian Federation, United Kingdom, Germany, Austria, Belgium, France, Hungary, South Africa, Romania, Bulgaria, Poland, Israel, Latvia, Ukraine, Lithuania, Netherlands
Bayer

Completed

Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

Pneumonia

Belgium, Germany, Spain, Greece, France, Netherlands, Chile, Mexico, Poland, South Africa, United Kingdom, Argentina, Colombia, Israel, Lithuania, Peru, Portugal, Sweden
Bayer

Completed

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection (MOXIPEDIA)

Intraabdominal Infections

Greece, Peru, United States, Chile, Bulgaria, Canada, Russian Federation, Lithuania, Germany, Hungary, Latvia, Romania, Ukraine, Czechia, Argentina, Mexico
Bayer

Completed

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Pelvic Inflammatory Disease

China, Philippines, Thailand, Pakistan, Taiwan, Indonesia, Korea, Republic of
Bayer

Completed

A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

Pneumonia

Italy
Bayer
RTI Health Solutions

Completed

Risk of Acute Liver Injury in Users of Antimicrobials

Drug-Induced Liver Injury

United States

Search clinical trials for: BAF312

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations